UY35985A - Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios. - Google Patents
Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios.Info
- Publication number
- UY35985A UY35985A UY0001035985A UY35985A UY35985A UY 35985 A UY35985 A UY 35985A UY 0001035985 A UY0001035985 A UY 0001035985A UY 35985 A UY35985 A UY 35985A UY 35985 A UY35985 A UY 35985A
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- pharmaceutical compositions
- diseases
- inflammatory disorders
- hypersecretion
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201402070A GB201402070D0 (en) | 2014-02-07 | 2014-02-07 | Pharmaceutical compositions for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35985A true UY35985A (es) | 2015-09-30 |
Family
ID=50390571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035985A UY35985A (es) | 2014-02-07 | 2015-02-06 | Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10493158B2 (https=) |
| EP (1) | EP3102213B1 (https=) |
| JP (1) | JP6633531B2 (https=) |
| AR (1) | AR099306A1 (https=) |
| AU (1) | AU2015215044B2 (https=) |
| CA (1) | CA2938217C (https=) |
| DK (1) | DK3102213T3 (https=) |
| ES (1) | ES2788671T3 (https=) |
| GB (1) | GB201402070D0 (https=) |
| HR (1) | HRP20200605T1 (https=) |
| NZ (1) | NZ722403A (https=) |
| TW (1) | TWI697330B (https=) |
| UY (1) | UY35985A (https=) |
| WO (1) | WO2015117980A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| NO2699580T3 (https=) | 2014-01-24 | 2018-02-24 | ||
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CN105198880B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物a晶型及其制备方法 |
| CN105198878B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物f晶型及其制备方法 |
| CN105198876B (zh) * | 2015-09-18 | 2017-09-29 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物h晶型及其制备方法 |
| CN105198877B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物g晶型及其制备方法 |
| CN105218539B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物b晶型及其制备方法 |
| CN105198879B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物c晶型及其制备方法 |
| CN105111206B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物e晶型及其制备方法 |
| CN105111207B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物d晶型及其制备方法 |
| EP3383363B1 (en) * | 2015-11-30 | 2021-01-06 | Anacor Pharmaceuticals, Inc. | Topical pharmaceutical formulations for treating inflammatory-related conditions |
| EP3434675A4 (en) * | 2016-03-21 | 2019-03-06 | Crystal Pharmatech Co., Ltd | HYDROCHLORIDE SALT CREAM OF A MEDICAMENT FOR TREATING OR PREVENTING JAC-ASSOCIATED DISEASES AND METHOD OF PRODUCTION THEREOF |
| JP2019534304A (ja) | 2016-11-10 | 2019-11-28 | ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． | 炎症性疾患の治療のための化合物及びその医薬組成物 |
| GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PL3595667T3 (pl) | 2017-03-14 | 2024-03-18 | Galapagos Nv | Kompozycje farmaceutyczne zawierające inhibitor jak |
| KR20250002710A (ko) * | 2018-03-01 | 2025-01-07 | 아스트라제네카 에이비이 | (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물 |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| AU2019306532A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis |
| PH12022552454A1 (en) * | 2020-04-14 | 2024-02-05 | Janssen Biotech Inc | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2026027676A1 (en) | 2024-07-31 | 2026-02-05 | Alfasigma S.P.A. | Biomarkers for determining treatment of ulcerative colitis with filgotinib |
| WO2026027669A1 (en) | 2024-07-31 | 2026-02-05 | Alfasigma S.P.A. | Biomarkers for determining treatment of ulcerative colitis with filgotinib |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000044722A1 (en) | 1999-01-29 | 2000-08-03 | Chugai Seiyaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
| US20040138285A1 (en) | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| CA2515190A1 (en) | 2003-02-14 | 2004-08-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| US20070004658A1 (en) | 2004-06-21 | 2007-01-04 | Nick Vandeghinste | Method and means for treatment of osteoarthritis |
| EP1786811A2 (en) | 2004-08-18 | 2007-05-23 | Pharmacia & Upjohn Company LLC | Triazolopyridine compounds |
| WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| WO2007018192A1 (ja) * | 2005-08-10 | 2007-02-15 | Shionogi & Co., Ltd. | 口腔内崩壊錠剤 |
| JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| US8053574B2 (en) | 2007-07-18 | 2011-11-08 | Novartis Ag | Organic compounds |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| CA2691448A1 (en) | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| BRPI0909945A2 (pt) | 2008-06-20 | 2015-07-28 | Genentech Inc | "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase" |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| CN102459258B (zh) | 2009-06-05 | 2015-11-25 | 赛福伦公司 | 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途 |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| AU2013279597B2 (en) | 2012-06-22 | 2017-04-20 | Alfasigma S.P.A. | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof |
| JP6041823B2 (ja) * | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
| GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2014
- 2014-02-07 GB GB201402070A patent/GB201402070D0/en not_active Ceased
-
2015
- 2015-02-04 DK DK15705777.9T patent/DK3102213T3/da active
- 2015-02-04 ES ES15705777T patent/ES2788671T3/es active Active
- 2015-02-04 US US14/614,393 patent/US10493158B2/en active Active
- 2015-02-04 WO PCT/EP2015/052239 patent/WO2015117980A1/en not_active Ceased
- 2015-02-04 JP JP2016550646A patent/JP6633531B2/ja active Active
- 2015-02-04 AU AU2015215044A patent/AU2015215044B2/en active Active
- 2015-02-04 CA CA2938217A patent/CA2938217C/en active Active
- 2015-02-04 HR HRP20200605TT patent/HRP20200605T1/hr unknown
- 2015-02-04 NZ NZ72240315A patent/NZ722403A/en unknown
- 2015-02-04 EP EP15705777.9A patent/EP3102213B1/en active Active
- 2015-02-06 UY UY0001035985A patent/UY35985A/es not_active Application Discontinuation
- 2015-02-06 TW TW104104150A patent/TWI697330B/zh active
- 2015-02-06 AR ARP150100350A patent/AR099306A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3102213A1 (en) | 2016-12-14 |
| NZ722403A (en) | 2019-09-27 |
| TW201613601A (en) | 2016-04-16 |
| CA2938217C (en) | 2023-03-07 |
| CA2938217A1 (en) | 2015-08-13 |
| US20150224199A1 (en) | 2015-08-13 |
| ES2788671T3 (es) | 2020-10-22 |
| DK3102213T3 (da) | 2020-05-04 |
| JP6633531B2 (ja) | 2020-01-22 |
| WO2015117980A1 (en) | 2015-08-13 |
| HRP20200605T1 (hr) | 2020-07-10 |
| AU2015215044A1 (en) | 2016-08-11 |
| TWI697330B (zh) | 2020-07-01 |
| US10493158B2 (en) | 2019-12-03 |
| AU2015215044B2 (en) | 2020-04-09 |
| GB201402070D0 (en) | 2014-03-26 |
| JP2017505330A (ja) | 2017-02-16 |
| AR099306A1 (es) | 2016-07-13 |
| EP3102213B1 (en) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35985A (es) | Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios. | |
| UY35984A (es) | Sales novedosas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| CR20140583A (es) | Aminotriazolopirimidina para uso en tratamiento de inflamación y composiciones farmacéuticas de la misma | |
| GT201700107A (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis | |
| CO2017013443A2 (es) | Composiciones que comprenden cepas bacterianas del género blautia | |
| CO2017013446A2 (es) | Composiciones que comprenden cepas bacterianas del género bacteroides | |
| CL2017003142A1 (es) | Composiciones que comprenden cepas bacterianas | |
| MX2016015724A (es) | Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1. | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| UY35975A (es) | Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia | |
| CR20110673A (es) | Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias | |
| MX2015011281A (es) | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| AR089960A1 (es) | Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias | |
| MX377534B (es) | Compuestos para usarse en el tratamiento de hiperinsulinemia. | |
| CL2016002615A1 (es) | Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos. | |
| PH12016501677B1 (en) | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2017002796A (es) | Tasimelteon para tratar el sindrome de smith-magenis. | |
| CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
| MX2017006043A (es) | Metodo y composiciones de anti-hcmv. | |
| MX380683B (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina. | |
| AR106769A1 (es) | Composiciones que comprenden cepas bacterianas | |
| MX376367B (es) | Activacion del factor x. | |
| AR104993A1 (es) | Composiciones comprendiendo cepas bacterianas del género parabacteroides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20221206 |